<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">9146011</PMID>
      <DateCompleted>
        <Year>1997</Year>
        <Month>06</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>07</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0090-4295</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>49</Volume>
            <Issue>5A Suppl</Issue>
            <PubDate>
              <Year>1997</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Urology</Title>
          <ISOAbbreviation>Urology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hydroxyzine therapy for interstitial cystitis.</ArticleTitle>
        <Pagination>
          <StartPage>108</StartPage>
          <EndPage>110</EndPage>
          <MedlinePgn>108-10</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the usefulness of oral hydroxyzine for the treatment of symptomatic interstitial cystitis.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This study was an open-label, nonconsecutive case series of patients treated by their local physicians, in consultation with the authors. A case-report form using visual analog scales was used to assess outcomes.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of 140 patients, 90 (65%) returned the case-report forms. A 40% reduction in symptom scores was reported. This rose to 55% in patients with a history of allergies.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hydroxyzine is a useful drug for the symptomatic treatment of IC, especially in patients with documented allergies and/or evidence of bladder mast cell activation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Theoharides</LastName>
            <ForeName>T C</ForeName>
            <Initials>TC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology / Experimental Therapeutics, Tufts University School of Medicine, New England Medical Center, Boston, Massachusetts 02111, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sant</LastName>
            <ForeName>G R</ForeName>
            <Initials>GR</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Urology</MedlineTA>
        <NlmUniqueID>0366151</NlmUniqueID>
        <ISSNLinking>0090-4295</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006634">Histamine H1 Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>30S50YM8OG</RegistryNumber>
          <NameOfSubstance UI="D006919">Hydroxyzine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018856" MajorTopicYN="N">Cystitis, Interstitial</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006634" MajorTopicYN="N">Histamine H1 Antagonists</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006919" MajorTopicYN="N">Hydroxyzine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1997</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1997</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1997</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9146011</ArticleId>
        <ArticleId IdType="doi">10.1016/s0090-4295(97)00182-9</ArticleId>
        <ArticleId IdType="pii">S0090-4295(97)00182-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
